Loading
A phase 3 trial of DCVax-L in Glioma & glioblastoma and Brain and spinal cord tumours, run by Northwest Biotherapeutics, with a status the registry has not verified recently.
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer is a phase 3 interventional study registered as NCT00045968 by Northwest Biotherapeutics, with 348 participants planned, started 2006-12 and due to reach its primary completion in 2022-11. Interventions recorded: Dendritic cell immunotherapy. Conditions recorded: Glioblastoma Multiforme, Glioblastoma, GBM, Grade IV Astrocytoma, Glioma, Brain Cancer, Brain Tumor.
Linked to the drug DCVax-L because the registry names it among its interventions and Glioma & glioblastoma and Brain and spinal cord tumours among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tag pipeline.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tag pipeline.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tag pipeline.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tag pipeline.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tag pipeline.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tag pipeline.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tag pipeline.
Shares Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/